Geographical differences in attention deficit hyperactivity disorder treatment rates across the UK
Exploration of Neuroprotective Therapy · 08.07.2026 · 6
DOI: 10.37349/ent.2026.1004163 ↗Kurz gefasst
Fachartikel in der Zeitschrift Exploration of Neuroprotective Therapy, online erschienen am 08.07.2026. Verfasst von Blandine French und 3 weiteren Autor:innen. Die Arbeit nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Aim
Attention deficit hyperactivity disorder (ADHD) is a common condition impacting approximately 5% of children and 3–4% of adults in the United Kingdom (UK). While it cannot be cured, treatment has been shown to positively impact the difficulties associated with ADHD. However, ADHD is widely underdiagnosed and undertreated in the UK. This paper reports the results of a model developed to estimate pharmacological treatment rates by area across National Health Service (NHS) integrated care systems (ICSs) in England, health boards in Scotland and Wales, and health & social care trusts (HSCTs) in Northern Ireland.
Methods
The model used the UK general population and ADHD prevalence data to estimate the number of patients with ADHD in each area. Prescription data for medicines licensed for the treatment of ADHD were then used to estimate the number of patients who are untreated and treated, and the percentage treatment rates by area. The analysis was descriptive, focusing on quantifying geographic variation in treatment rates.
Results
Nationally, the estimated proportions of children and young people (CYP; 5–17 years) and adults (18–65 years) treated were 26.6% and 15.6%, respectively, of the expected ADHD populations. Treatment rates by ICS or health board in England, Scotland, and Wales ranged from 11.7% to 60.6% for the CYP population and 8.6% to 24.8% for the adult population (data for Northern Ireland were not available by age group). Overall treatment rates (ages 5–65 years) in Northern Ireland ranged from 6.7% in the lowest-ranking HSCT to 31.1% in the highest-ranking HSCT.
Conclusions
In the UK, there is currently a high degree of geographic variation across all NHS systems and a generally low level of treatment of ADHD, especially in adults. Up to a 4.6-fold difference in pharmacological treatment rates was observed between NHS service provider areas.
Zitieren
APA
French, B., Davies, J., Williams, C., & Kirby, A. (2026). Geographical differences in attention deficit hyperactivity disorder treatment rates across the UK. Exploration of Neuroprotective Therapy, 6. https://doi.org/10.37349/ent.2026.1004163
Vancouver
French B, Davies J, Williams C, Kirby A. Geographical differences in attention deficit hyperactivity disorder treatment rates across the UK. Exploration of Neuroprotective Therapy. 2026;6. doi:10.37349/ent.2026.1004163
BibTeX
@article{French2026,
author = {French, Blandine and Davies, James and Williams, Chris and Kirby, Amanda},
title = {Geographical differences in attention deficit hyperactivity disorder treatment rates across the UK},
journal = {Exploration of Neuroprotective Therapy},
year = {2026},
volume = {6},
doi = {10.37349/ent.2026.1004163}
}
EUVIMED